IFF's Scent recovery hinges on a strengthened R&D pipeline and a revamped go-to-market strategy, with Consumer Fragrance poised for market-share gains while Fine Fragrance navigates regional volatility. The company frames 2027 as a natural extension of its enhanced R&D capabilities, with a shift toward higher-value, natural ingredients and sustained innovation to support growth in the second half and beyond.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management attributes Scent’s recovery to a mix of R&D capability rebuild, commercial execution / market-share drive, and normalizing dynamics in Fragrance Ingredients and Fine Fragrance.
Management says the R&D pipeline quality has improved materially over the last ~2.5 years, including moving from being “falling behind” to having a “very strong R&D capability,” “great perfumers,” and a “great pipeline of molecules as well as delivery systems.” 1
For Consumer Fragrance, management specifically links progress to “rebuild the R&D capability [and] go-to-market approach with customers” and “trying to drive market share gains.” 2
For Fine Fragrance, management highlights operational ability to manage “challenges in the Middle East,” noting that while growth was expected to be down in Fine Fragrance mid-single digits coming into the quarter, it instead “finished up slightly positive.” 3
Scent performance is also described as benefiting from Fragrance Ingredients strength—Q2 Sales were up 8% with Fragrance Ingredients “grew north of 20%,” and management says the team “strategically leveraged the synthetics portfolio” to capture more sales amid macro/supply chain conditions (including higher Brent crude). 3 However, they also state that as conditions settle, growth should “normalize” and shift back toward “higher value-added ingredients versus the traditional synthetics.” 3 (This is important because the “recovery” is not portrayed as purely cyclical; management frames it as repositioning toward higher-value natural products “underway,” taking more time.) 2
Management expects Fine Fragrance to be:
The underlying rationale combines cyclic/region volatility with tough year-over-year comps: management notes Middle East-related uncertainty continues and they are “factoring in a softer Q3,” partly because Q3 last year grew 20% (a difficult comparison). 3
Implication for the “recovery” narrative: Fine Fragrance is not described as uniformly recovering each quarter; it’s framed as a Q3 dip then Q4 rebound driven by both volatility management and comparisons. 23
Management expects Consumer Fragrance to remain relatively steadier, with:
Implication: Consumer Fragrance is more “range-bound” than Fine Fragrance near term—Q2 outperformance is expected to fade, but management still sees it moving forward with low single-digit growth on a go-forward basis. 2
The excerpts provide a clear directional R&D plan (capability + pipeline + delivery systems), but not a detailed multi-year roadmap with specific projects. Still, management describes several elements that are directly intended to support evolution into 2027.
Management says that R&D is no longer at the earlier “falling behind” stage and now includes:
This is the foundation they cite for being “optimistic about the future of Scent.” 1
For Consumer Fragrance, management ties recovery to “rebuild the R&D capability [and] go-to-market approach with customers,” explicitly aiming for “market share gains.” 2
So the R&D plan is not just product innovation; it is innovation integrated with customer engagement and execution. 2
While the question is specifically about R&D supporting 2027, the excerpts indicate that the shift toward higher-value natural products in Fragrance Ingredients is “underway,” and it “will take a little bit more time” and is expected to yield a “really strong competitive position” as you go into “next year and the year after.” 2
Even though this statement is about Fragrance Ingredients (within Scent), it functions as an R&D-supported competitive positioning strategy for the 2027 horizon. 2
Management acknowledges they are “not satisfied” and still have work to do, but they emphasize strengthening strengths and addressing gaps, backed by the improved pipeline and perfumer capabilities. 1
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF's Scent recovery is anchored in a rebuilt R&D engine and stronger go-to-market execution, with near-term tailwinds from fragrance ingredients. 2H 2026 guidance shows Fine Fragrance accelerating into Q4 while Consumer Fragrance normalizes to low single-digit growth, as Middle East volatility subsides. The 2027 plan focuses on a robust pipeline and higher-value ingredient mix to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent’s rebound to a rebuilt R&D engine, stronger perfumers, and improved go-to-market execution, while guiding a softer Q3 and stronger Q4 for Fine Fragrance and a normalized low single-digit path for Consumer Fragrance in 2H. The company also emphasizes an expanded R&D program—molecules, delivery systems, and higher-value ingredients—to sustain growth into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi‑driver path to Scent recovery, led by Fragrance Ingredients momentum, improved Consumer and Fine Fragrance execution, and an R&D overhaul aimed at 2027. In 2H, Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance normalizes from a high single-digit Q2 growth to a low single-digit trajectory, supported by a revamped product pipeline and go‑to‑market strategy.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by stronger Fragrance Ingredients, stabilization in Fine Fragrance, and a rebuilt Consumer Fragrance engine anchored by R&D and go-to-market improvements. The 2H 2026 path points to a Q3 softness followed by a Q4 rebound, with a longer runway toward 2027 supported by an 8–9% R&D intensity and a strengthened innovation pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by strong Fragrance Ingredients growth and a rebuilt R&D engine, with a mid-to-long-term plan to enhance market position into 2027. In H2, Fine Fragrance is expected to soften in Q3 and rebound in Q4, while Consumer Fragrance trends toward low single-digit growth as R&D and go-to-market initiatives support share gains.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent’s rebound to robust Fragrance Ingredients growth and an improved R&D pipeline, with plans to support 2027. Fine Fragrance is expected to be softer in Q3 and stronger in Q4, while Consumer Fragrance normalizes to a low single-digit growth profile.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent rebound in Q2 2026 rests on normalization of Fragrance Ingredients, resilient Fine Fragrance execution amid Middle East volatility, and a rebuild of R&D and go-to-market for Consumer Fragrance. Management signals a mid‑single‑digit H2 for Fine Fragrance and low single-digit growth for Consumer Fragrance, underpinned by an improved R&D pipeline and a long-term push into 2027 with higher-value ingredients and delivery systems.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 results underscore a resilient Scent recovery driven by double-digit Fragrance Ingredients growth and solid Consumer Fragrance momentum, with a rebuilt R&D pipeline set to support growth into 2027. In the second half, Fine Fragrance is expected to soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace as R&D and go-to-market improvements support market share gains.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management attributes Scent's rebound to a rebuilt R&D engine and stronger go-to-market execution, with 2H expected to show mid-single-digit growth for Fine Fragrance and low-single-digit gains for Consumer Fragrance, while Fragrance Ingredients normalizes. The plan emphasizes sustained R&D investment around 8-9% of sales to support a pipeline of molecules, delivery systems, and innovative products through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by stronger Fragrance Ingredients, a cautious but improving Fine Fragrance trajectory through Middle East volatility, and a Consumer Fragrance rebound driven by rebuilt R&D and go-to-market capabilities aimed at market-share gains. The plan emphasizes a multi-year R&D rebuild, a deep pipeline of molecules and delivery systems, and an innovation-first path to 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF attributes Scent's rebound to Fragrance Ingredients momentum, with Fine Fragrance stabilizing amid volatility and Consumer Fragrance propelled by an R&D-led recovery and go-to-market rebuild. The company expects a mid-single-digit 2H for Fine Fragrance and a low single-digit pace for Consumer Fragrance, supported by a strengthened R&D pipeline targeting 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a multi-faceted Scent recovery driven by stabilizing Fine Fragrance demand, normalization of Consumer Fragrance through revamped R&D and go-to-market execution, and a shift toward higher-value Fragrance Ingredients. The firm also details a robust 2027 R&D plan designed to sustain competitive advantage with an strengthened pipeline, leading-edge perfumers, and sustained reinvestment in innovation, aligned to long-term growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi